Article

A Roundup of This Week's #CureFacts

Author(s):

CURE staff

Did you know that naked mole rats are immune to cancer? Here's a weekly roundup of #CureFact

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Robotic and minimally invasive kidney cancer surgery may reduce pain, shorten recovery time and preserve kidney function, according to Dr. Armine Smith.
2 experts are featured in this series.
2 experts are featured in this series.
Image of Doctor.
Building long-term trust with providers can help patients with MPNs feel supported, encourage them to speak up and navigate care with confidence.
The field of radiation oncology has advanced in brain cancer treatment with precise therapeutic approaches including proton and carbon therapy.
Image of Dr. Doug
Image of doctor.
Image of Dr. Kelly
Image of Dr. Boffa.
Related Content
Image of bladder.
May 15th 2025

Bladder Cancer Awareness Month Highlights the Importance of Early Detection

Ryan Scott
Dr. Daniel P. Petrylak sits down with CURE during Bladder Cancer Awareness Month to discuss key topics for patients with the disease.
The Importance of Spotting Endometrial Cancer
March 18th 2025

The Importance of Spotting Endometrial Cancer

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.
Chester Freeman was diagnosed with bladder cancer and most recently with chronic lymphocytic leukemia (CLL). Read more of Chester's blogs here!
May 15th 2025

Finding Comfort in Teddy Bears Throughout My Experience With CLL

Chester Freeman
As a patient with CLL, I’ve found comfort in teddy bears — first as a chaplain offering solace, now as a patient embracing their quiet presence myself.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
Efti and Keytruda comboo achieves a 61% response rate in first-line advanced non-squamous non–small cell lung cancer: © stock.adobe.com.
May 15th 2025

Efti Plus Keytruda With Chemo Shows High Response in NSCLC Subset

Spencer Feldman
Efti plus Keytruda and chemo achieved a 61% response rate in first-line advanced non-squamous non–small cell lung cancer, outperforming historical data.
Lumakras plus Vectibix showed improved overall survival and response rates in KRAS G12C metastatic colorectal cancer, though not statistically significant.
May 15th 2025

Lumakras Plus Vectibix Shows Potential in KRAS G12C Colorectal Cancer

Spencer Feldman
Lumakras plus Vectibix showed improved overall survival and response rates in KRAS G12C metastatic colorectal cancer, though not statistically significant.